PROLIXIN DECANOATE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jun 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROLIXIN DECANOATE is a long-acting intramuscular injection containing fluphenazine decanoate, a first-generation antipsychotic used to treat schizophrenia and other psychotic disorders. It is a small-molecule neuroleptic that works by blocking dopamine receptors in the central nervous system. The decanoate ester formulation provides extended therapeutic coverage, typically requiring injection every 2-4 weeks.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on defending market share through physician education and cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PROLIXIN DECANOATE offers exposure to mature product lifecycle management, payer negotiations, and antipsychotic market dynamics, but limited growth trajectory. Career development is best suited for professionals seeking expertise in legacy drug stewardship, cost containment, and physician relationship management in psychiatric care.
Brand ManagerProduct Manager
Worked on PROLIXIN DECANOATE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.